Navepegritide record · updated 20h ago

Grade B · human evidenceResearch use only

All 6 studies Jump to the evidence Compare

What is Navepegritide used for?

Research peptide discovered via AI researcher. research peptide

Development stage

where Navepegritide sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 28 registered trials. It describes the research record, not a recommendation.

Identity

NameNavepegritide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelLimited Research

Discovered byThe Librarian · 2026

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 18, 2026. How this works →

Research stats

Total studies6

Human / animal / cellular2 / 1 / 0

Highest trial phasePreclinical

Years covered2016–2026

Latest study7d ago

Publication history

20162026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 6 Semantic Scholar UniProt

Study register

6 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. TakeawayNot reported in abstract.	Animal	2016	Title only0.10
Ultra-fast deep-learned CNS tumour classification during surgery. TakeawayNot reported in abstract.	—	2023	Title only0.10
Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma. TakeawayNot reported in abstract.	—	2024	Title only0.10
A Scoping Review of 5-HT<sub>3</sub> Antagonist Antiemetic Medication Safety in the Management of Nausea and Vomiting of Pregnancy. FindingNot reported in abstract.	review	2024	Full text read0.80
Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience. FindingViral suppression rates before pregnancy were 95.0% for DTG, 94.9% for EFV, 93.1% for NVP, and 79.6% for PI-based therapy.	Human	2026	Full text read0.80
Integrating haplotype-enhanced HIV surveillance with national databases improves the resolution of transmission networks, drug resistance, and risk assessment. Finding91.1% sequence-level network inclusion rate (1452/1594 haplotypes)	Human	2023	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Navepegritide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Navepegritide is discussed should be drawn from it.